Company registration number 07866886 (England and Wales)
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
CONTENTS
Page
Company information
1
Balance sheet
2 - 3
Notes to the financial statements
4 - 9
Detailed trading and profit and loss account
12-13
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
COMPANY INFORMATION
- 1 -
Director
Mr Mehmet Gazvani
Company number
07866886
Registered office
Riverside House
Kings Reach Business Park
Yew Street
Stockport
Cheshire
SK4 2HD
Accountants
Xeinadin
Riverside House
Kings Reach Business Park
Yew Street
Stockport
SK4 2HD
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 2 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
4
83,343
109,481
Current assets
Debtors
5
322,690
343,586
Cash at bank and in hand
323,729
249,475
646,419
593,061
Creditors: amounts falling due within one year
6
(144,377)
(116,368)
Net current assets
502,042
476,693
Total assets less current liabilities
585,385
586,174
Creditors: amounts falling due after more than one year
7
(36,667)
(76,667)
Provisions for liabilities
(2,550)
(4,642)
Net assets
546,168
504,865
Capital and reserves
Called up share capital
8
100
100
Profit and loss reserves
546,068
504,765
Total equity
546,168
504,865
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024
31 December 2024
- 3 -
For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved and signed by the director and authorised for issue on 29 September 2025
Mr Mehmet Gazvani
Director
Company registration number 07866886 (England and Wales)
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -
1
Accounting policies
Company information
Reproductive Medicine & Gynaecology Associates Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Riverside House, Kings Reach Business Park, Yew Street, Stockport, Cheshire, SK4 2HD.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Going concern
The financial statements have been prepared on a going concern basis.true
1.3
Turnover
Turnover comprises the fair value of the consideration received and provision of services in the ordinary course of the company’s activities.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.
1.4
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Leasehold improvements
10% straight line
Plant and equipment
33/25% straight line
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.5
Borrowings
Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
1.6
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.7
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.8
Financial instruments
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 6 -
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.9
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
1.10
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.11
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 7 -
1.12
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Total
3
3
3
Operating profit/(loss)
2024
2023
Operating profit/(loss) for the year is stated after charging:
£
£
Depreciation of tangible fixed assets
26,421
25,214
4
Tangible fixed assets
Leasehold improvements
Plant and equipment
Total
£
£
£
Cost
At 1 January 2024
113,529
97,829
211,358
Additions
283
283
At 31 December 2024
113,529
98,112
211,641
Depreciation and impairment
At 1 January 2024
29,030
72,847
101,877
Depreciation charged in the year
11,353
15,068
26,421
At 31 December 2024
40,383
87,915
128,298
Carrying amount
At 31 December 2024
73,146
10,197
83,343
At 31 December 2023
84,499
24,982
109,481
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
14,619
Amounts owed by group undertakings and undertakings in which the company has a participating interest
290,925
300,195
Other debtors
17,146
43,391
322,690
343,586
6
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
40,000
40,000
Trade creditors
49,832
2,209
Taxation and social security
28,143
2,872
Other creditors
26,402
71,287
144,377
116,368
7
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
36,667
76,667
Creditors amounts falling due after one year includes the following includes liabilities on which security has been given by the company:
There is a Debenture including a Fixed and Floating Charge over all present freehold and leasehold property in favour of Lloyds Bank PLC.
8
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary share of £1 each
100
100
100
100
REPRODUCTIVE MEDICINE & GYNAECOLOGY ASSOCIATES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 9 -
9
Related party transactions
Summary of transactions with other related parties
At the balance sheet date the amount due from the director was £8,323 (2023: £46). This is on an interest free basis and repayable on demand.
During the year, the company was charged rent and service charges on an arms length basis from Reproductive Immunology Associates Limited totalling £18,000 (2023: £18,000).
At the balance sheet date the company was owed £290,925 (2023: £300,431) from a company in which Mr Mehmet Rafet Gazvani is a director.
10
Operating lease commitments
Lessee
The amount of non-cancellable operating lease payments recognised as an expense during the year was £14,814 (2023: £22,744).
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:
2024
2023
£
£
Total commitments
26,156
54,587
11
Control
The company is controlled by the director who owns 100% of the called up share capital.
2024-12-312024-01-01falsefalsefalse29 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr Mehmet Gazvani078668862024-01-012024-12-31078668862024-12-3107866886bus:Director12024-01-012024-12-3107866886bus:RegisteredOffice2024-01-012024-12-31078668862023-12-3107866886core:LeaseholdImprovements2024-12-3107866886core:PlantMachinery2024-12-3107866886core:LeaseholdImprovements2023-12-3107866886core:PlantMachinery2023-12-3107866886core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3107866886core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3107866886core:ShareCapital2024-12-3107866886core:ShareCapital2023-12-3107866886core:RetainedEarningsAccumulatedLosses2024-12-3107866886core:RetainedEarningsAccumulatedLosses2023-12-3107866886core:ShareCapitalOrdinaryShareClass12024-12-3107866886core:ShareCapitalOrdinaryShareClass12023-12-3107866886core:LeaseholdImprovements2024-01-012024-12-3107866886core:PlantMachinery2024-01-012024-12-31078668862023-01-012023-12-3107866886core:LeaseholdImprovements2023-12-3107866886core:PlantMachinery2023-12-31078668862023-12-3107866886core:CurrentFinancialInstruments2024-12-3107866886core:CurrentFinancialInstruments2023-12-3107866886core:WithinOneYear2024-12-3107866886core:WithinOneYear2023-12-3107866886core:Non-currentFinancialInstruments2024-12-3107866886core:Non-currentFinancialInstruments2023-12-3107866886bus:OrdinaryShareClass12024-01-012024-12-3107866886bus:OrdinaryShareClass12024-12-3107866886bus:OrdinaryShareClass22023-12-3107866886bus:PrivateLimitedCompanyLtd2024-01-012024-12-3107866886bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3107866886bus:FRS1022024-01-012024-12-3107866886bus:AuditExemptWithAccountantsReport2024-01-012024-12-3107866886bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP